MNG34
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.239
- KRAS_SIGNALING_DN+0.179
- ANDROGEN_RESPONSE+0.170
- HEDGEHOG_SIGNALING+0.141
- G2M_CHECKPOINT+0.126
- NOTCH_SIGNALING+0.100
- MITOTIC_SPINDLE+0.096
- PANCREAS_BETA_CELLS+0.087
- UV_RESPONSE_DN+0.082
- E2F_TARGETS+0.073
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.608
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.433
- DNA_REPAIR-0.418
- MYC_TARGETS_V2-0.392
- TNFA_SIGNALING_VIA_NFKB-0.391
- ADIPOGENESIS-0.365
- UNFOLDED_PROTEIN_RESPONSE-0.359
- MYC_TARGETS_V1-0.358
- GLYCOLYSIS-0.355
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.347
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8e33d29d-23c9-48f4-89a2-d0a9b17d0081 | — | — | 0.828 |
| 2 | SRR627462 | GTEX | — | 0.805 |
| 3 | MNG214 | — | — | 0.803 |
| 4 | 4b4a3828-d808-4d25-a06c-b738fd8daacb | — | — | 0.801 |
| 5 | SRR627449 | GTEX | — | 0.799 |
| 6 | MNG189 | — | — | 0.796 |
| 7 | SRR627455 | GTEX | — | 0.794 |
| 8 | MNG355 | — | — | 0.793 |
| 9 | MNG13 | — | — | 0.790 |
| 10 | SRR627429 | GTEX | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.239 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.179 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.141 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.126 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.096 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.087 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.082 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.073 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.072 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.056 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.035 | Inavolisib | — uncovered |
| MYOGENESIS | 0.035 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.031 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.029 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.014 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.012 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |